AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9751449 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 18
Study 7842354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1,000 mg/day for 2 weeks)
Number of subjects: 8
Study 7842354 — intervention group
Group type: COMPARATOR
Intervention: Inert inositol tablets (control)
Number of subjects: 8
Study 2896383 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil (3 mg daily for 4 weeks)
Number of subjects: 107
Study 2896383 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 g daily for 4 weeks)
Number of subjects: 107
Study 2896383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 107
Study 2896383 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil
Number of subjects: 107
Study 2896383 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 107
Study 28325104 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-4 (4 hours/week for 8 weeks)
Number of subjects: 9
Study 28325104 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-8 (8 hours/week for 8 weeks)
Number of subjects: 9
Study 28325104 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-4 and Hybrid-8
Number of subjects: 9
Study 26456161 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin Nano Ceramic (RNC) crowns bonded to zirconia abutments
Number of subjects: 50
Study 26456161 — intervention group
Group type: COMPARATOR
Intervention: Reference standard (not explicitly mentioned as a control group)
Number of subjects: 50
Study 24682975 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC ads with placebo rates
Number of subjects: 2000
Study 24682975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed frame DTC ads
Number of subjects: 2000
Study 24682975 — intervention group
Group type: COMPARATOR
Intervention: Placebo/single frame ad
Number of subjects: 2000
Study 23522365 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave sintering
Number of subjects: 32
Study 23522365 — intervention group
Group type: COMPARATOR
Intervention: Conventional sintering
Number of subjects: 32
Study 19481275 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 40
Study 19481275 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy (KT)
Number of subjects: 40
Study 19481275 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy + Electrical Stimulation (KT+ES)
Number of subjects: 40
Study 19481275 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study 19033150 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (Drinking Less) without therapist guidance.
Number of subjects: 261
Study 16632138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 7127
Study 16632138 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 7127
Study 12381251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (20 mg once daily)
Number of subjects: 307
Study 12381251 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 307
Study 10480346 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized antibody against HER2 (Herceptin)
Number of subjects: 0
Study 10480346 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized antibody against HER2 (Herceptin) combined with chemotherapy
Number of subjects: 0
Study 10480346 — intervention group
Group type: COMPARATOR
Intervention: Control group (unspecified)
Number of subjects: 0
Study 8548972 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% lignocaine ointment
Number of subjects: 0
Study 8548972 — intervention group
Group type: COMPARATOR
Intervention: Standard vaseline gauze pack
Number of subjects: 0
Study 2331632 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent facial expression with verbal feedback
Number of subjects: 71
Study 2331632 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent facial expression with verbal feedback
Number of subjects: 71
Study 2331632 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stimuli (face or verbal)
Number of subjects: 71
Study 7442577 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped lectures via CCTV
Number of subjects: 61
Study 7442577 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 61
Study 31095949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve (Bif195)
Number of subjects: 75
Study 31095949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 28718049 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin using a handheld, battery-operated, breath-actuated inhaler with aerosol generators producing 3-6 μm particle size distribution.
Number of subjects: 0
Study 28718049 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin with inspiratory flow of 10 L/min guided by LED.
Number of subjects: 0
Study 25497721 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fibrinogen group (fibrinogen levels < 2 g/L or decreased by 25% or more)
Number of subjects: 104
Study 25497721 — intervention group
Group type: COMPARATOR
Intervention: Normal fibrinogen group (fibrinogen levels not meeting low criteria)
Number of subjects: 104
Study 25497721 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 104
Study 25497721 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical severity and hypofibrinogenemia
Number of subjects: 104
Study 24176449 — intervention group
Group type: EXPERIMENTAL
Intervention: PEB + BMS
Number of subjects: 125
Study 24176449 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 125
Study 21379417 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether plus lumefantrine (A+L)
Number of subjects: 656
Study 21379417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin plus piperaquine (DHA+PQ)
Number of subjects: 656
Study 21379417 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with chloroquine plus sulfadoxine plus pyrimethamine (CQ+S+P)
Number of subjects: 656
Study 21379417 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine plus pyrimethamine (AS+S+P)
Number of subjects: 656
Study 19910721 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATM) 40-100 mg per day, n = 14
Number of subjects: 27
Study 19910721 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 13
Number of subjects: 27
Study 19910721 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATM)
Number of subjects: 27
Study 19910721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19910721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 17908591 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT-152 (100 microg in 100 microl phosphate buffer) administered via 4 subconjunctival injections before and after trabeculectomy and at 1 week post-surgery.
Number of subjects: 388
Study 17908591 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered via 4 injections before and after trabeculectomy and at 1 week post-surgery.
Number of subjects: 388
Study 17908591 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT-152
Number of subjects: 388
Study 14961887 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg BD for 12 weeks
Number of subjects: 494
Study 14961887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 11311926 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MP)
Number of subjects: 9
Study 11311926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9241341 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine (2-CP)
Number of subjects: 42
Study 9241341 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine (2-CP) + epinephrine (Epi, 5 micrograms.ml-1)
Number of subjects: 42
Study 9241341 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine (Lido) + epinephrine (Epi)
Number of subjects: 42
Study 8363422 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30 mg i.v. over 5 minutes)
Number of subjects: 270
Study 8363422 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (10 mg bolus + 5000 IU of heparin as a bolus, followed by 90 mg rt-PA over 3 hours)
Number of subjects: 270
Study 8363422 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 MU in 1 hour)
Number of subjects: 270
Study 3097293 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (50 mumol/kg/day)
Number of subjects: 14
Study 3097293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31724913 — intervention group
Group type: EXPERIMENTAL
Intervention: High source credibility
Number of subjects: 207
Study 31724913 — intervention group
Group type: COMPARATOR
Intervention: Low source credibility
Number of subjects: 207
Study 31724913 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed messages
Number of subjects: 207
Study 31724913 — intervention group
Group type: COMPARATOR
Intervention: Positively framed messages
Number of subjects: 207
Study 31378383 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g)
Number of subjects: 119
Study 31378383 — intervention group
Group type: COMPARATOR
Intervention: Combination (1 g paracetamol, 400 mg ibuprofen, 60 mg codeine)
Number of subjects: 119
Study 28331155 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib monotherapy (NSAID group)
Number of subjects: 33
Study 28331155 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises (exercise group)
Number of subjects: 33
Study 26005933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuning in to Teens (TINT) program
Number of subjects: 449
Study 24024705 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP-first
Number of subjects: 257
Study 24024705 — intervention group
Group type: COMPARATOR
Intervention: MRCP-first
Number of subjects: 257
Study 21598207 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational group therapy, performed regularly 6 days a week
Number of subjects: 56
Study 21598207 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 56
Study 19546766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 85 mg and naproxen sodium 500 mg (sumatriptan-naproxen)
Number of subjects: 621
Study 17008408 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in PDE9A and PDE11A
Number of subjects: 284
Study 17008408 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in PDE1A and PDE11A
Number of subjects: 284
Study 17008408 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE11A haplotype GAACC
Number of subjects: 284
Study 15281544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand-guided intubation in supine position
Number of subjects: 120
Study 15281544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand-guided intubation in left lateral position
Number of subjects: 120
Study 15281544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand-guided intubation in right lateral position
Number of subjects: 120
Study 10619939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithoclast
Number of subjects: 46
Study 10619939 — intervention group
Group type: COMPARATOR
Intervention: Electrokinetic Lithotripter (EKL)
Number of subjects: 46
Study 9184950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 micrograms every 4 hours up to 600 micrograms)
Number of subjects: 123
Study 9184950 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (standard protocol by continuous infusion)
Number of subjects: 123
Study 9184950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 123
Study 9184950 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 123
Study 1587572 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and coracoclavicular screw fixation (20 patients)
Number of subjects: 48
Study 1587572 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management (28 patients)
Number of subjects: 48
Study 1587572 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and coracoclavicular screw fixation
Number of subjects: 48
Study 1587572 — intervention group
Group type: EXPERIMENTAL
Intervention: Late salvage surgery (6 patients)
Number of subjects: 48
Study 4091236 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine equivalent prick (HEP) standard allergen extracts
Number of subjects: 0
Study 4091236 — intervention group
Group type: COMPARATOR
Intervention: Protein nitrogen units (PNU) standard allergen extracts
Number of subjects: 0
Study 3297376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride (AZP) 2 mg/kg for 4 doses
Number of subjects: 29
Study 3297376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride (AZP) 2 mg/kg for 4 doses + Dexamethasone (DXM) 8 mg for five doses
Number of subjects: 29
Study 3297376 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MCP) 1 mg/kg for four doses + Dexamethasone (DXM) 8 mg for five doses
Number of subjects: 29
Study 31135965 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28490227 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric with spinners
Number of subjects: 151
Study 28490227 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric with icon arrays
Number of subjects: 151
Study 28490227 — intervention group
Group type: COMPARATOR
Intervention: Numeric only
Number of subjects: 151
Study 25422488 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-cyclophosphamide administered continuously
Number of subjects: 3250
Study 25422488 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel administered once per week
Number of subjects: 3250
Study 25422488 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-cyclophosphamide administered once every 2 weeks
Number of subjects: 3250
Study 25422488 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel administered once every 2 weeks
Number of subjects: 3250
Study 22235762 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical mallet (magnetic mallet, Meta‐Ergonomica)
Number of subjects: 36
Study 22235762 — intervention group
Group type: COMPARATOR
Intervention: Hand mallet
Number of subjects: 36
Study 21515996 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care service (n=36) including physical therapy, acupuncture, western medicines or herbal medicines
Number of subjects: 85
Study 21515996 — intervention group
Group type: COMPARATOR
Intervention: Western care (n=49) including physical therapy or western medicines
Number of subjects: 85
Study 21515996 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care service (n=36)
Number of subjects: 85
Study 19630713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological aids (e.g., nicotine replacement therapy, bupropion)
Number of subjects: 0
Study 19630713 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally- or psychosocially-based interventions
Number of subjects: 0
Study 16963397 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up after completion of therapy
Number of subjects: 32
Study 12858323 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 53
Study 12858323 — intervention group
Group type: COMPARATOR
Intervention: Zaleplon 10 mg
Number of subjects: 53
Study 10840912 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture (with no phrase)
Number of subjects: 129
Study 10840912 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrase (with no picture)
Number of subjects: 129
Study 10840912 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture and phrase
Number of subjects: 129
Study 10840912 — intervention group
Group type: COMPARATOR
Intervention: No picture and no phrase
Number of subjects: 129
Study 9589359 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinamide II (RII) suppositories, 10 mg QD, given intravaginally for 6 months (each course lasting 3 months)
Number of subjects: 27
Study 9589359 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinamide II (RII) suppository intravaginally, once daily for 50 days in two courses
Number of subjects: 27
Study 9589359 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily for 50 days in two courses
Number of subjects: 27
Study 8494776 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vibration at 100 Hz with 100 shocks per second at 2.5, 5, or 10 ms‐2 rms
Number of subjects: 0
Study 8494776 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive shocks at 5 shocks per second at 2.5, 5, or 10 ms‐2 rms
Number of subjects: 0
Study 8494776 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no vibration
Number of subjects: 0
Study 3915206 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle ear irrigation during tympanostomy tube insertion
Number of subjects: 220
Study 3915206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 220
Study 30880777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/day) for 4 weeks
Number of subjects: 20
Study 30880777 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 20
Study 29100706 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 4081
Study 29100706 — intervention group
Group type: COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 4081
Study 25186452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutanplast
Number of subjects: 100
Study 25186452 — intervention group
Group type: COMPARATOR
Intervention: Spongostan
Number of subjects: 100
Study 23829417 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported telemetric monitoring of glycemic control and blood pressure
Number of subjects: 320
Study 23829417 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 21098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens intake (isoflavonoids/lignans/coumestrol)
Number of subjects: 47140
Study 21098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake (vegetable/cereal)
Number of subjects: 47140
Study 21098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific food items rich in phytoestrogens (berries, nuts, beans/soy, crisp or whole-grain bread)
Number of subjects: 47140
Study 21098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber and coumestrol intake
Number of subjects: 47140
Study 19375954 — intervention group
Group type: EXPERIMENTAL
Intervention: Full preparation (2-L polyethylene glycol solution with 20 mL of sodium diatrizoate)
Number of subjects: 101
Study 19375954 — intervention group
Group type: COMPARATOR
Intervention: Minimum preparation (45 mL of sodium diatrizoate and 10 mL of sodium picosulfate solution)
Number of subjects: 101
Study 19375954 — intervention group
Group type: EXPERIMENTAL
Intervention: Full preparation
Number of subjects: 101
Study 19375954 — intervention group
Group type: COMPARATOR
Intervention: Minimum preparation
Number of subjects: 101
Study 17552046 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 20
Study 17552046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15466736 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-dish rotating platform
Number of subjects: 50
Study 15466736 — intervention group
Group type: COMPARATOR
Intervention: Anterior-posterior gliding mobile bearing
Number of subjects: 50
Study 15466736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 11841770 — intervention group
Group type: COMPARATOR
Intervention: No microorganism (no-group)
Number of subjects: 70
Study 11841770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas (Ps-group)
Number of subjects: 70
Study 11841770 — intervention group
Group type: EXPERIMENTAL
Intervention: Other microorganisms (another-group)
Number of subjects: 70
Study 10682564 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine (0.4 ml hypodermically injected per day for 7 days)
Number of subjects: 20
Study 10682564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 8583438 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (Fleet PhosphoSoda)
Number of subjects: 79
Study 8583438 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol electrolyte (PEG) solution (GoLYTELY)
Number of subjects: 79
Study 2243264 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-directed health education program
Number of subjects: 78
Study 2243264 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-paced health education program
Number of subjects: 78
Study 632455 — intervention group
Group type: EXPERIMENTAL
Intervention: .3 mg/kg of Ritalin
Number of subjects: 20
Study 632455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification
Number of subjects: 20
Study 632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin and Behavior modification
Number of subjects: 20
Study 31122890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1000
Study 31122890 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 1000
Study 31122890 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning symbol
Number of subjects: 1000
Study 31122890 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating system (HSR)
Number of subjects: 1000
Study 31122890 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Intakes (RIs)
Number of subjects: 1000
Study 31462288 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy regimens (specific regimens not detailed)
Number of subjects: 145
Study 31462288 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for patients with weight loss ≥10% at baseline
Number of subjects: 145
Study 28075381 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (480 mg DHA and 720 mg EPA per day)
Number of subjects: 86